Over the past two decades, monoclonal antibody technology has had an increasing impact on clinical diagnostic and therapeutic options, and this is true in the realm of managing prostate cancer. Several targets such as prostate speci®c antigen and prostatic acid phosphatase, as well as, more recently, angiogenic antigens such as vascular endothelial growth factor have been examined for therapy. The role of immunotherapeutic modalities in prostate cancer (PCa) has only recently been explored. Adenocarcinoma of the prostate has always been regarded as a less immunogenic tumour. Routine light microscopic observations of paraf®n-embedded prostate tissue does not show massive in®ltration of immune cells in PCa. However, recent observations in prostate cancer indicate immunological entities, both humoral and cellular. High intratumoural levels of TGF-b mRNA are correlated with poor prognosis in hormone refractory prostate cancer, indicating a local immune suppressive environment. Also, the ®nding that cytokine modulation can alter PCa properties which is closely associated with tumour invasion and a metastatic phenotype, suggests that immunotherapy may have a potential role in the treatment of hormone refractory PCa. Recent observations in our laboratory of single cell suspensions of PCa tissue revealed a consistent massive in®ltration of tumour in®ltrating lymphocytes with potential tumour killing capacity. These data suggest that an immune cell environment exists in prostate tumours. Despite the need for new prostate-speci®c therapeutic and diagnostic targets, very few unique prostate (cancer) speci®c antigenic structures have been de®ned by monoclonal antibody (mAb) technology. This is partly due to dif®culties inherent in the identi®cation of tissue speci®c hybridomas; preferably, primary fusion products must be screened by immunohistochemistry. However, due to the polyclonality of the primary cells and the large number, this is not feasible. Here the initial results of the generation of new prostate (cancer) speci®c mAbs using alternative screening methods are presented.
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Method
Splenocytes from mice immunised with mixtures of homogenates obtained from fresh frozen PCa specimens were fused using standard techniques. Cells were grown in soft agarose under selection conditions. Sterile nitrocellulose ®lters coated with PCa homogenates or coated with irrelevant tissue homogenates were used for differential high-throughput screening. Clones showing reactivity with the PCa coated ®lter only were isolated and grown in suspension. Thereafter hybridomas were screened by immunohistochemistry.
Results
From 16 fusions (approximately 30 000 hybridomas), 301 hybridomas were identi®ed excreting PCa-reactive antibodies by the initial ®lter screening. Eventually one clone (mAb3.10) showed consistent homogenous reactivity with normal prostate and all PCa tissues, from both primary (n 18) and metastatic (n 7) lesions, irrespective of Gleason grade. In contrast, no cross-reactivity with any of the normal tissues tested (from 26 different organs), including peripheral blood lymphocytes, was observed. Furthermore, no cross-reactivity was observed with non-prostate tumours (from 10 different organs). By Western blot analysis we excluded reactivity with PSA and/or PSMA.
Conclusion
MAb 3.10 de®nes a new prostate speci®c antigen, the expression of which is consistent in all PCa cells, irrespective of metastatic potential. This antigen may provide a new diagnostic and/or therapeutic target. Additional ®ne-speci®city studies are needed to decide whether this MAb can be used as a diagnostic and/or therapeutic tool. Molecular analysis of antigen recognised is in progress.
